Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Andrade | $482,095 | $70,551 | $1,117,500 | $202,878 | $0 | $0 | $0 | $1,873,024 |
| Chief Financial Officer | ||||||||
| Jeffrey Hackman | 586,343 | 45,833 | 887,100 | 202,878 | 0 | 0 | 0 | 1,722,154 |
| Chief Executive Officer | ||||||||
| Pierre Sayad | 464,081 | 0 | 311,000 | 0 | 0 | 0 | 0 | 775,081 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Andrade | $1,873,024 | — | — | — |
| Jeffrey Hackman | 1,722,154 | — | — | — |
| Pierre Sayad | 775,081 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dr. Khalid Islam | Option | 25,000 | 8.78 | — |
| Dr. Jodi Cook | Option | 20,000 | 5.4 | — |
| Dr. Marco Brughera | Option | 20,000 | 7.52 | — |
| Dr. Khalid Islam | Option | 25,000 | 4.26 | — |
| Mr. Chris A. Rallis | Option | 14,344 | 2.44 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 5.1 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 10.93 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 8.78 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 4.26 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 6.17 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 7.52 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 5.59 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 5.58 | — |
| Mr. Chris A. Rallis | Option | 20,000 | 7.88 | — |
| Dr. Khalid Islam | Option | 25,000 | 5.1 | — |
| Dr. Khalid Islam | Option | 25,000 | 10.93 | — |
| Dr. Khalid Islam | Option | 25,000 | 6.17 | — |
| Dr. Khalid Islam | Option | 25,000 | 7.52 | — |
| Dr. Khalid Islam | Option | 25,000 | 5.59 | — |
| Dr. Khalid Islam | Option | 25,000 | 5.58 | — |
| Dr. Khalid Islam | Option | 25,000 | 7.88 | — |
| Dr. Marco Brughera | Option | 35,545 | 2.11 | — |
| Dr. Marco Brughera | Option | 20,000 | 5.1 | — |
| Dr. Marco Brughera | Option | 20,000 | 10.93 | — |
| Dr. Marco Brughera | Option | 20,000 | 4.26 | — |
| Dr. Marco Brughera | Option | 20,000 | 6.17 | — |
| Dr. Jodi Cook | Option | 20,000 | 6.17 | — |
| Dr. Marco Brughera | Option | 20,000 | 5.59 | — |
| Dr. Marco Brughera | Option | 20,000 | 8.78 | — |
| Dr. Marco Brughera | Option | 20,000 | 5.58 | — |
| Dr. Marco Brughera | Option | 20,000 | 7.88 | — |
| Dr. Jodi Cook | Option | 20,000 | 5.59 | — |
| Dr. Jodi Cook | Option | 20,000 | 8.78 | — |
| Dr. Jodi Cook | Option | 20,000 | 5.58 | — |
| Dr. Jodi Cook | Option | 20,000 | 7.88 | — |
| Dr. Jodi Cook | Option | 20,000 | 7.52 | — |
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 19,326,750 | 336,060 | 710,677 | 98.29% | Passed |
| 2025 | 2025-06-03 | 12,110,598 | 1,595,423 | 456,870 | 88.36% | Passed |
| 2024 | 2024-06-25 | 9,830,484 | 346,881 | 294,143 | 96.59% | Passed |
| 2023 | 2023-06-12 | 15,855,506 | 134,025 | 5,087 | 99.16% | Passed |
| 2022 | 2022-06-14 | 12,812,365 | 153,550 | 52,058 | 98.82% | Passed |
| 2021 | 2021-06-29 | 13,354,125 | 343,244 | 148,564 | 97.49% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 98.29%a |
| 2025 | 2025-06-03 | 88.36%b |
| 2024 | 2024-06-25 | 96.59%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Khalid IslamIndependent · Audit | $100,000 | $0 | $114,019 | — | — | $214,019 |
| Mr. Chris A. RallisIndependent · Audit (Chair) · Nominating/Governance · Compensation | 82,500 | 0 | 91,215 | — | — | 173,715 |
| Dr. Marco BrugheraIndependent · Audit · Nominating/Governance · Compensation (Chair) | 77,500 | 0 | 91,215 | — | — | 168,715 |
| Dr. Jodi CookIndependent · Nominating/Governance (Chair) · Compensation | 62,500 | 0 | 91,215 | — | — | 153,715 |
| Rosty RaykovIndependent · Not standing for re-election | 0 | 0 | 0 | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $322,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $322,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Fennec Pharmaceuticals | 2025 | Jeffrey Hackman | $586,343 | $887,100 | $202,878 | $0 | $1,722,154 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Andrade | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Executive Compensation”. As printed: 1,873,024. Filing ↗ |
| 2 | Section 01, Jeffrey Hackman | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Executive Compensation”. As printed: 1,722,154. Filing ↗ |
| 3 | Section 01, Pierre Sayad | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Executive Compensation”. As printed: 775,081. Filing ↗ |
| 4 | Section 08, Dr. Khalid Islam | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Director Compensation”. As printed: 214,019. Filing ↗machine: span 577202–577209 |
| 5 | Section 08, Mr. Chris A. Rallis | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Director Compensation”. As printed: 173,715. Filing ↗machine: span 587148–587155 |
| 6 | Section 08, Dr. Marco Brughera | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Director Compensation”. As printed: 168,715. Filing ↗machine: span 580513–580520 |
| 7 | Section 08, Dr. Jodi Cook | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Director Compensation”. As printed: 153,715. Filing ↗machine: span 583578–583585 |
| 8 | Section 08, Rosty Raykov | DEF 14A | 2026-04-28 | 0001104659-26-050339 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 06, 2026 vote | Form 8-K | 2026-06-10 | 0001104659-26-072425 | Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 19,326,750). Filing ↗ |
| 10 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0001104659-25-055992 | Item 5.07 · say-on-pay result. As reported: 88.36% (votes for as printed: 12,110,598). Filing ↗ |
| 11 | Section 06, 2024 vote | Form 8-K | 2024-06-25 | 0001104659-24-074748 | Item 5.07 · say-on-pay result. As reported: 96.59% (votes for as printed: 9,830,484). Filing ↗ |
| 12 | Section 09b board cost (computed) | Computed | — | computed | Cash 322,500 + equity 0 + all other 0 = 322,500, summed across the director compensation table rows.machine: formula: Σ = 322,500 |
| 13 | Fennec Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050339 | CEO total compensation as printed in Fennec Pharmaceuticals's own proxy. As printed: 1,722,154. Filing ↗ |